Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
CROSSMARK LOGO Buy Reprints
PDF

Translate this page into:

Case Letter
87 (
3
); 383-385
doi:
10.25259/IJDVL_654_18
pmid:
33666061

Familial drug reaction with eosinophilia and systemic symptoms syndrome

Department of Dermatology, Hospital Clínic de Barcelona, Universitat De Barcelona, Spain
Department of Dermatology, Hospital Sant Joan De Déu, Barcelona, Spain
Corresponding author: Dr. Asunción Vicente-Villa, Department of Dermatology, Hospital Sant Joan de Déu, Passeig Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain. avicente@sjdhospitalbarcelona.org
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Morgado-Carrasco D, Fustà-Novell X, Mascaró JM Jr., Gonzalez-Enseñat MA, Vicente-Villa A. Familial drug reaction with eosinophilia and systemic symptoms syndrome. Indian J Dermatol Venereol Leprol 2021;87:383-5.

Sir,

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is an infrequent delayed hypersensitivity reaction to drugs characterized by rash, fever, eosinophilia, lymphadenopathy and systemic involvement. DRESS syndrome can even cause death and early suspension of the culprit drug is essential.1 There is a genetic predisposition.2 Here, we present a case of simultaneous DRESS syndrome in a father and son after starting antitubercular therapy.

A previously healthy 38-year-old South American man and his 9-year-old son was started on antitubercular treatment after they were both diagnosed with pulmonary tuberculosis. The father was given rifampin 600 mg/day, isoniazid 300 mg/ day, pyrazinamide 1600 mg/day and ethambutol 1100 mg/ day. The son weighed 31 kg and was started on rifampin 300 mg/day, isoniazid 150 mg/day, pyrazinamide 800 mg/day and ethambutol 550 mg/day. Two weeks later both presented with fever, odynophagia and pruritic skin lesions. On physical examination, they showed a generalized erythematous maculopapular rash [Figures 1a, b and c] and facial edema. Cervical, axillary and inguinal lymphadenopathies were found in both. Blood tests showed leukocytosis (29,600/ mm3 in father and 13,100/mm3 in son), eosinophilia (4,600/ mm3 in father and 2,800/mm3 in son) and elevation of liver transaminases (aspartate aminotransferase 552 IU/L in father and 67 IU/L in son, alanine aminotransferase 301 IU/L in father and 302 IU/L in son). Chest X-ray of the father revealed an interstitial pneumonitis. Blood cultures were negative. Serology (IgM and IgG) and polymerase chain reaction (PCR) on peripheral blood samples for herpes virus type 7, cytomegalovirus, Epstein Barr virus, measles, parvovirus B19 and mycoplasma pneumoniae were negative in both patients. The father showed a positive PCR for herpes virus type 6 but was negative in his son. He underwent a skin biopsy and histology showed an interface dermatitis and a perivascular inflammatory infiltrate with lymphocytes and eosinophils in the dermis [Figures 2a and b].

Figure 1a:: Erythematous maculopapular rash on the father’s chest and upper limbs
Figure 1b:: Erythematous maculopapular rash on the father’s back
Figure 1c:: Erythematous maculopapular rash on the son’s lower abdomen and anterior aspect of the thighs
Figure 2a:: Epidermal spongiosis, focal interface dermatitis and a perivascular and peri-appendageal inflammatory infiltrate with lymphocytes and eosinophils in the dermis (hematoxylin and eosin, ×40)
Figure 2b:: Perivascular inflammatory infiltrate with lymphocytes and eosinophils in the dermis (red arrow) (hematoxylin and eosin, ×100)

Both patients fulfilled the criteria of the International Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) (8 and 6 points respectively) for definitive diagnosis (>5 points) of DRESS syndrome [Table 1].1

Table 1:: Clinical and laboratory findings in father and son affected with drug reaction with eosinophilia and systemic symptoms syndrome
Patient/age (years) Culprit drug and dose (mg/day) Time from drug intake to the onset of symptoms (days) Clinical presentation Blood tests and X-rays Serology, PCR* and blood culture PCR of **HHV-6 Histological findings RegiSCAR score***
Father/38 Rifampin: 600
Isoniazid: 300
Pyrazinamide: 1600
Ethambutol: 1100
15 Fever
Morbilliform rash affecting
>50% BS**** (1 point)
Facial and acral edema, purpura (1 point)
Polyadenopathies (1 point)
AST/ALT*****: 552/301 UI/L (liver involvement: 1 point)
4600×106eosinophils (2 points)
Interstitial pneumonitis (lung involvement: 1 point)
Negative (exclusion of other potential causes: 1 point) Positive Interface dermatitis, eosinophils in dermis 8 (definitive diagnosis)
Son/9 Rifampin: 300
Isoniazid: 150
Pyrazinamide: 800
Ethambutol: 550
15 Fever
Morbilliform rash
Facial edema, purpura (1 point)
Polyadenopathies (1 point)
AST/ALT: 67/302 UI/L (liver involvement: 1 point)
2800×106eosinophils (2 points)
Negative (exclusion of other potential causes: 1 point) Negative Not performed 6 (definitive diagnosis)
Serology , PCR : polymerase chain reaction of herpes virus type 7, cytomegalovirus, Epstein Barr virus, measles, parvovirus B19 and Mycoplasma pneumoniae, **HHV-6: human herpes virus 6, ***RegiSCAR score : registry of severe cutaneous adverse reactions score, <2 no case, 2-3 possible case, 4-5 probable case, 6-9 definite case. ****BS: body surface, *****AST: aspartate aminotransferase, ALT: alanine aminotransferase

Antitubercular treatment was discontinued and oral corticosteroids were initiated (1 mg/kg/day). Both showed resolution of their symptoms and rash in the following 4 weeks and progressive normalization of laboratory tests during the following 8 weeks. The patients completed second-line antitubercular treatment with amikacin, levofloxacin and ethambutol without further complications. On genetic testing, the father did not present any known human leukocyte antigen (HLA) associated with DRESS syndrome (his HLA was DRB1*07, DRB1*08, A*02, A*24, B*40, B*44). The parents did not give consent to carry out genetic tests in the child. The patients were lost to follow-up and patch tests could not be performed.

The physiopathology of DRESS syndrome remains elusive. It involves reactivation of the herpesvirus family, altered immune response and genetic predisposition. Multiple HLA polymorphisms have been described, mostly in the Asian population, that confer greater susceptibility to severe hypersensitivity reactions. Interestingly, it seems that certain HLA variants are associated with specific drugs and specific cutaneous adverse reactions. HLA-A*31:01 and HLA-B*51:01 showed significant association with carbamazepine-induced DRESS,2 HLA-B*5801 has been linked to allopurinol-induced DRESS3 and HLA-B*5701 to abacavir-induced hypersensitivity reactions in both whites and blacks.4 The exact mechanism by which an HLA interacts with a drug and is capable of triggering an abnormal immune response is unknown. Only in the case of abacavir has a noncovalent binding between the drug and the HLA molecule been demonstrated. Such modifications of the immune presentation are endogenous and self-proteins induce polyclonal CD8 T-cell activation and a systemic reaction.5

Although adverse cutaneous effects of antitubercular drugs are frequent, DRESS syndrome is rarely seen. We could not find any report of HLA associated with antitubercular drug-induced DRESS but with our findings we suspect that an association could exist.

We have presented a rare case of a father and son who simultaneously developed a serious drug reaction, highlighting that there is a genetic predisposition for DRESS syndrome. Clinical suspicion was fundamental in excluding the differential diagnosis of a viral infection, a pathology that was more likely in contacts.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , , , , et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction, Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071-80.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Genotype phenotype association between HLA and carbamazepine induced hypersensitivity reactions: Strength and clinical correlations. J Dermatol Sci. 2014;73:101-9.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. HLA B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134-9.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. High sensitivity of human leukocyte antigen b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111-8.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , , et al. Immune self reactivity triggered by drug modified HLA peptide repertoire. Nature. 2012;486:554-8.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
903

PDF downloads
314
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections